Bainbridge–Ropers Syndrome (ASXL3-Related Disorder) — Comprehensive Research Report

Prepared: 2026-07-31 · Target: Bainbridge-Ropers syndrome · Category: Mendelian, autosomal dominant, chromatinopathy / neurodevelopmental

Verification note (per dismech DR policy): Every PMID below was retrieved from Europe PMC / NCBI E-utilities during this session, and quoted material is taken from the retrieved abstract text. Ontology identifiers marked [verify] were assigned by me from domain knowledge and have not been checked with OAK — run just validate-terms before committing. Identifiers marked [OLS-checked] were confirmed against OLS4 in this session. HPO annotations in §3 were pulled directly from the HPO annotation API for OMIM:615485 and carry authoritative ID↔label pairs.

NEC preflight: MONDO:0014205 xrefs to OMIM:615485 and ORPHA:352577; the causal gene named across all retrieved sources is uniformly ASXL3 (18q12.1). No named-entity confusion detected. The main confusable entities are the sibling ASXL disorders (ASXL1/Bohring–Opitz, ASXL2/Shashi–Pena) — these are distinct diseases and are explicitly treated as differential diagnoses below, not as synonyms.

1. Disease Information

1.1 Overview

Bainbridge–Ropers syndrome (BRPS), increasingly referred to in the clinical genetics literature as ASXL3-related disorder, is a rare autosomal dominant neurodevelopmental syndrome caused by heterozygous loss-of-function (predominantly de novo truncating) variants in ASXL3. It was delineated in 2013 by Bainbridge, Ropers and colleagues through whole-genome/whole-exome sequencing of four undiagnosed probands (PMID:23383720).

The core phenotype is: global developmental delay / moderate-to-severe intellectual disability, profoundly limited or absent speech, infantile hypotonia, feeding difficulties with failure to thrive, autistic features and other neurobehavioral problems, and a recognizable craniofacial gestalt.

A concise contemporary definition (PMID:41659201, Front Neurosci 2025):

"Bainbridge-Ropers syndrome (BRPS, OMIM #615485) is a rare, heterogeneous autosomal dominant genetic disease that is mainly characterized by intellectual disability (ID) of varying degrees, developmental delay (DD), language impairments, failure to thrive, behavioral issues, hypotonia, feeding difficulties, and distinctive craniofacial features. It is caused by heterozygous pathogenic variants in the additional sex combs-like 3 (ASXL3, OMIM #615115) gene."

BRPS belongs to the chromatinopathies / Mendelian disorders of the epigenetic machinery, and specifically to the ASXL family disorder triad:

1.2 Key identifiers

1.3 Synonyms and alternative names

• Bainbridge-Ropers syndrome / BRPS
• ASXL3-related disorder (preferred by GeneReviews and by the Balasubramanian/Woods group; increasingly the recommended label because the phenotype extends beyond the original BRPS description)
• ASXL3-related syndrome
• Severe feeding difficulties–failure to thrive–microcephaly due to ASXL3 deficiency syndrome (Orphanet/MONDO label)
• "Bainbridge-Roppers syndrome" (misspelling retained as a MONDO exact synonym)
• ASXL3 deficiency syndrome
• Historically: "Bohring–Opitz-like syndrome" (superseded — see §10.4)

1.4 Provenance of information

Information in this report is disease-level aggregated (OMIM, Orphanet, GeneReviews, MONDO, ClinGen, HPO, ClinVar) plus individual-patient literature (case reports and multi-centre cohort series totalling >200 published individuals). There is no EHR-derived / registry-scale phenotyping dataset. The closest to systematic patient-level data are:

• The International ASXL3 Natural History Study (IRAS 316055; 64 individuals, PMID:40552904) — quasi-natural-history design, direct clinic/caregiver consultation.
• The ARRE Foundation patient advocacy registry (ASXL Rare Research Endowment) supporting the ASXL1/2/3 deep-phenotyping work at UCLA/CHLA (PMID:38027485, PMID:40808361).
• The DDD (Deciphering Developmental Disorders) study and DECIPHER, which supplied several published cohorts (PMID:28100473, PMID:29367179, PMID:34436830).

2. Etiology

2.1 Disease causal factors

BRPS is a monogenic, primarily de novo, haploinsufficiency disorder. There is no infectious, toxic, or acquired etiology.

Primary cause: heterozygous loss-of-function variants in ASXL3 — nonsense, frameshift, and canonical splice-site variants clustered in exons 11 and 12.

Founding evidence (PMID:23383720, Genome Med 2013, HUMAN_CLINICAL):

"Using genome-wide sequencing, we identified heterozygous, de novo truncating mutations in ASXL3, a transcriptional repressor related to ASXL1, in four unrelated probands. We found that these probands shared similar phenotypes, including severe feeding difficulties, failure to thrive, and neurologic abnormalities with significant developmental delay."

Mechanism of disease causation per GeneReviews (ASXL3-Related Disorder, NBK563693, Balasubramanian & Schirwani): "Loss of function." ClinGen Dosage Sensitivity assigns haploinsufficiency score 3 — Sufficient Evidence for Haploinsufficiency (last evaluated 2017-11-22), citing a haploinsufficiency index of 13.78 and pLI 1.00.

2.2 Risk factors

Genetic risk factors

1. Causal variants — see §4. Essentially all reported pathogenic variants are protein-truncating (PTV) or splice-site.
2. Parental germline / gonosomal mosaicism — a bona fide recurrence-risk factor. GeneReviews: "Sib recurrence due to presumed parental germline mosaicism has been reported in three families." Confirmed by ultra-deep sequencing (PMID:40980137, 2025):

   "We definitively diagnosed this family by WES and found the lowest level of paternal mosaicism reported to date, with a peripheral blood variant allele frequency (VAF) of 8.17% and a semen VAF of 15.03%." Also PMID:42194125 (2026): a clinically unaffected mother mosaic at ~15% VAF in peripheral blood DNA transmitted c.1648_1649del; p.Met550Aspfs*5 to two half-brothers.

3. Inherited variants from a mildly affected parent — established (PMID:36177608; PMID:42494517).
4. Advanced paternal age — the generic de novo mutation risk factor. Not specifically quantified for ASXL3; evidence gap.
5. Modifier / second-locus effects — see §4.3.

Environmental risk factors: None identified. No toxin, teratogen, occupational, dietary, or infectious risk factor has been associated with BRPS. Sex does not appear to be a strong risk modifier (see §9.4). Not applicable / no evidence.

2.3 Protective factors

No genetic or environmental protective factors have been identified. Two adjacent observations are worth recording:

• Reduced penetrance / mild expression. GeneReviews and PMID:34436830 explicitly discuss "nonpenetrance" and mildly affected individuals; PMID:33242595 notes "The exact molecular mechanism of these mutations resulting in the disease phenotype is still uncertain due to the observation of LOF mutations in healthy population." Whatever buffers these individuals is unknown — an important open question, not a documented protective factor.
• A potentially "protective"/therapeutic window exists in the mouse model: neonatal thyroid hormone supplementation rescues behaviour, but adolescent supplementation does not (bioRxiv PPR1237608; see §6.1 and §12.3).

2.4 Gene–environment interactions

No documented GxE interaction. The single mechanistic candidate arising from the 2026 mouse work is a gene–hormone/nutrient interaction: Asxl3 haploinsufficiency depletes brain thyroid hormone via DIO3 derepression, which in principle makes early-life thyroid status a modifiable environmental variable. This is model-organism-only and unvalidated in humans.

3. Phenotypes

3.1 GeneReviews frequency table (authoritative aggregate)

GeneReviews ASXL3-Related Disorder (NBK563693), Table "Select Features of ASXL3-Related Disorder" — reproduced as printed (confirmed on two independent retrievals):

Independent systematic review (PMID:38420660, Clin Genet 2024, Woods et al.):

"Common phenotypic features comprised global developmental delay or intellectual disability (97%), feeding problems (76%), hypotonia (88%) and characteristic facial features (93%)."

Spanish cohort, n=22 (PMID:39833101, Clin Genet 2025):

"The predominant prenatal finding was intrauterine growth restriction (35%) followed, after birth, by feeding difficulties (90.5%), hypotonia (85.7%), and gastroesophageal reflux disease (82.4%). Later in life, intellectual disability, language impairment, autism spectrum disorder (75%), and joint laxity (73.7%) were noted."

DDD cohort, n=12 (PMID:28100473, J Med Genet 2017):

"severe intellectual disability (11/12), poor/ absent speech (12/12), autistic traits (9/12)" … hypotonia 11/12, feeding difficulties 9/12.

3.2 HPO annotations (from HPO annotation API, OMIM:615485)

These are the authoritative curated HPO ID↔label↔frequency triples. Frequencies are n/N as curated from source publications (small denominators — treat as qualitative, not population estimates).

Neurodevelopmental / behavioral

Neurologic / tone

Growth / feeding / GI

Craniofacial

Ophthalmologic

Musculoskeletal / limb

Neuroimaging

Other systems

3.3 Additional / expanding phenotypes not yet in the HPO annotation set

These are recent, well-documented additions worth curating with their own evidence:

• Hyperventilation–athetosis (PMID:28955728, Neurol Genet 2017, Dad et al.). Hyperventilation escalating with nervousness, with athetotic movements developing in both upper extremities, especially the hands; interpreted as evidence of "a neural connection, in the context of ASXL3 deficiency, between pathways of respiration and of motor control." Suggested terms: HP:0002883 Hyperventilation [verify], HP:0002305 Athetosis [verify].
• Breath-holding spells with dystonic posturing, no ictal EEG correlate; refractory (PMID:35172777). Refractory to iron, acetazolamide, desipramine.
• Dystonic cerebral palsy phenotype (PMID:35863334, Neuropediatrics 2022): "infantile-onset limb/trunk dystonic postures and secondarily evolving distal spastic contractures." Authors conclude "ASXL3 should be added to target-gene lists used for molecular evaluation of cerebral palsy." Terms: HP:0001332 Dystonia [verify], HP:0002061 Lower limb spasticity [verify].
• Developmental coordination disorder (PMID:38027485, Front Neurosci 2023): "100% of individuals who underwent the development questionnaire met a diagnosis of developmental coordination disorder." n=7 ASXL3; hypotonia predominant in BRS vs mixed hypo/hypertonia in BOS.
• Renal phenotype (emerging), obesity in later childhood, antenatal/neonatal structural anomalies, lower-than-expected seizure prevalence (PMID:40552904, 2025):

  "Findings include: an increased prevalence of antenatal and neonatal structural anomalies, an emerging renal phenotype, a tendency for poor post-natal growth (with novel reports of obesity later in childhood), and a lower-than-expected prevalence of seizures (compared to the existing literature)."

• Sleep apnea — statistically enriched in the NMD and MCR1 subgroups (PMID:42494517). Term: HP:0010535 Sleep apnea [verify].
• Oro-dental: high-arched palate, narrow maxilla, posterior crossbite, open bite, fibrotic frenulum, mouth breathing (PMID:40237215, 2025).
• Prenatal / fetal: arthrogryposis on ultrasound with neuropathological pontocerebellar hypoplasia type 1 (PMID:29316359). Terms: HP:0002505 Arthrogryposis multiplex congenita [verify], HP:0007034 Pontocerebellar hypoplasia [verify].
• Cardiac: congenital laryngeal cartilage hypoplasia and dextrocardia reported as novel complications (PMID:41659201, 2025). Term: HP:0001651 Dextrocardia [verify].
• Progressive cerebral/cerebellar atrophy in a severe case (PMID:35172777). Term: HP:0002059 Cerebral atrophy [verify], HP:0001272 Cerebellar atrophy [verify].
• Precocious/premature pubarche signals — but note the ASXL1/BOS group carried the stronger signal; "Findings between the BOS (ASXL1) and BRS (ASXL3) individuals differed, representing distinct pubertal phenotypes within these populations" (PMID:40808361, 2026).
• Adolescent-onset feeding difficulty / ARFID — first report (PMID:38711055, 2024), notable because feeding problems otherwise typically improve with age.
• Precursor B-cell acute lymphoblastic leukemia — a single pediatric co-occurrence (PMID:35733401). Interpretation caution: this is n=1; ASXL1/ASXL2 are established somatic myeloid drivers, so a germline ASXL3 cancer predisposition is biologically speculative and unproven. Do not curate as an established association.

3.4 Phenotype characteristics

Age of onset. Congenital to neonatal. IUGR/polyhydramnios/arthrogryposis may be detected prenatally (35% IUGR, PMID:39833101). Hypotonia, feeding difficulty and failure to thrive are apparent in the neonatal period; developmental delay becomes evident in infancy; seizures are childhood-onset (PMID:29367179); ASD diagnosis typically in early childhood.

Severity. Highly variable. Historically described as severe, but the spectrum now clearly extends to mild. PMID:40552904: "We report significant phenotypic variability… We also provide the first qualitative descriptions of several mildly affected probands, at different ages." Some carriers of inherited variants are clinically unaffected or minimally affected.

Progression. Non-degenerative and largely static with improvement trends, which is prognostically important:

"…improvement trends in feeding, hypotonia, verbalisation, and motor skills over time." (PMID:40552904)

Counter-signals: hypotonia may transition to spasticity/contractures (GeneReviews; PMID:35863334); one severe case showed progressive cerebral/cerebellar atrophy (PMID:35172777); one case had adolescent-onset feeding decline (PMID:38711055).

Course patterns. Chronic lifelong. Seizures are episodic (GTCS ± atypical absence). Breath-holding/hyperventilation episodes are paroxysmal. Behavioral crises can be episodic and treatable (PMID:39698206).

3.5 Quality-of-life impact

No disease-specific EQ-5D/SF-36/PROMIS data exist for BRPS — evidence gap. Available proxies:

• Motor impairment → school engagement. PMID:38027485 reports motor impairments "negatively impact school engagement" and are "meaningful intervention targets."
• Unmet rehabilitation need. PMID:42111080 (Front Neurol 2026): "There exists limited evidence-based medical care and rehabilitation regimen for individuals with BRPS. Thus, the health care needs of individuals with BRPS are hugely unmet."
• Caregiver-facing burden of behavior. PMID:34086428: sleep impairment 71%, disruptive behavior 57%, aggression 57%, self-injurious behavior 43%; "All 7 patients (100%) had multiple DSM-5 diagnoses."
• Communication. Near-universal absent/limited speech is the single largest driver of functional dependency.
• A generic instrument potentially applicable: QI-Disability / QID-12 for children with intellectual disability (PMID:41920472) — not yet applied to BRPS.

4. Genetic / Molecular Information

4.1 Causal gene

ASXL3 (ASXL transcriptional regulator 3), 18q12.1, NCBI Gene 80816, OMIM 615115, HGNC:29357, aliases BRPS, KIAA1713. Reference transcript NM_030632.3. The gene's coding sequence is dominated by two very large exons (11 and 12), which is where essentially all pathogenic variants fall.

ClinGen Gene–Disease Validity: ASXL3 — Syndromic intellectual disability (MONDO:0000508) — Autosomal dominant — DEFINITIVE, Intellectual Disability and Autism GCEP, classified 2021-10-06. ClinGen explicitly notes: "ASXL3 will be curated for syndromic intellectual disability because of the variability in reported phenotypes that don't necessarily fall within the bounds of Bainbridge-Ropers syndrome."

4.2 Pathogenic variants

Variant class distribution. Overwhelmingly protein-truncating: nonsense and frameshift, plus canonical splice-site variants. PMID:38420660: "The majority of genetic variants were de novo truncating variants in exon 11 or 12 of the ASXL3 gene." GeneReviews detection rates: sequence analysis 98–99%, gene-targeted del/dup 1–2%, CMA rarely.

Mutational cluster regions (MCRs). Two clusters are consistently described. The most precise coordinates come from PMID:42494517 (2026):

• MCR1 = c.1095_2237, exon 11 (n=66 published individuals)
• MCR2 = c.3043_4906, exon 12 (n=101 published individuals)

MCR2 was the "second mutation cluster region" first identified in PMID:28100473.

Representative published variants (all NM_030632.3, all confirmed de novo unless noted):

Recurrent variants (useful for prioritization): p.Arg1444*, p.Arg1560*, p.Gln1512* — a systematic recurrent-variant analysis is in PMID:42494517.

ACMG/AMP classification. PTVs in the established MCRs meeting de novo criteria are typically Pathogenic (PVS1 + PS2 + PM2). Inherited PTVs are more difficult: PMID:42494517 cautions that family reports "may reflect uncertainty about the pathogenicity of inherited ASXL3 variants."

ClinVar (queried 2026-07-31, NCBI E-utilities): 1,086 total records for ASXL3[gene]; 453 records with Pathogenic or Likely Pathogenic clinical significance. (Counts are record-level, not unique-allele-level — treat as approximate.)

Population allele frequency / constraint. ASXL3 is among the most LoF-constrained genes in the genome: - pLI = 1.00 (ClinGen dosage curation, citing gnomAD/ExAC) - Haploinsufficiency Index = 13.78 (ClinGen) - pLI 0.9999 in ExAC (SFARI Gene) - LOEUF ≈ 0.23 (gnomAD v4.0) — reported via secondary source only in this session; [verify against gnomAD directly]**

Pathogenic BRPS variants are absent from gnomAD (PM2). Caveat worth curating: PMID:33242595 notes "the observation of LOF mutations in healthy population", which is why the disease mechanism at MCR level is still debated (see §4.4).

Somatic vs germline. BRPS variants are germline (constitutional) or parental mosaic. ASXL3 is not an established somatic cancer driver (unlike ASXL1/ASXL2 in myeloid neoplasia). Somatic ASXL3 mutations appear incidentally in tumour sequencing (e.g., neuroendocrine prostate cancer, ccRCC, T-cell lymphoma studies retrieved in this session) but with no established driver role.

Functional consequence — the NMD vs no-NMD dichotomy. This is now the leading mechanistic axis. From PMID:42494517 (2026):

"Statistical comparisons were made between individuals with variants leading to no protein product (nonsense-mediated messenger RNA decay [NMD], n = 87) and those with protein-truncating variants (no-NMD, n = 117)." "Microcephaly, sleep apnea, hyperventilation, and feeding tube use had a statistically increased prevalence in the NMD and MCR1 groups. Intellectual disability and global developmental delay were more severe in the NMD and MCR1 groups and were significant for the MCR1/MCR2 comparison (P = .0031 and P = .0183). Although autistic features were observed across all groups, the no-NMD and MCR2 cohorts had a higher proportion of individuals with formal autism diagnoses."

This implies two mechanisms coexist: true haploinsufficiency (NMD, MCR1 — more severe, more microcephaly) and a truncated-protein / possible dominant-negative or gain-of-function effect (no-NMD, MCR2 — more formal autism diagnoses). NMD of the mutant allele was directly demonstrated in patient fibroblasts (PMID:26647312): "ASXL3 mRNA transcripts from the mutated allele are prone to nonsense-mediated decay, and expression of ASXL3 is reduced."

Genotype–phenotype correlation status. Contradictory across sources — worth curating as a live controversy: - GeneReviews (2020): "No genotype-phenotype correlations for ASXL3 have been identified." - PMID:39833101 (2025): "Individuals with variants in the 3' mutational cluster region (MCR) of exon 12 exhibited more perinatal feeding problems, and those with variants in the 5' MCR of exon 11 displayed lower percentiles in height and occipitofrontal circumference, as well as higher frequency of arched eyebrows." - PMID:42494517 (2026): statistically significant MCR1 vs MCR2 differences (above).

Verdict: correlations are emerging and now statistically supported, superseding the earlier "none identified" statement.

Missense variants. Not established as a cause of the autosomal dominant disorder. GeneReviews: "Missense variants are not thought to be causative for autosomal dominant inheritance. Biallelic missense variants have been reported in four individuals with congenital heart defects; further evidence needed." PMID:34436830 and PMID:38420660 both flag "the disease contribution of missense variants" as an open gap. Separately, PMID:32132929 notes: "Human genomic studies also identified missense ASXL3 variants associated with autism spectrum disorder, but lacking more severe Bainbridge-Ropers syndromic features."

4.3 Modifier genes and multilocus variation

• 15q11.2 BP1–BP2 microdeletion as a modifier. PMID:41458212 (2025) reports a 7-month-old with a de novo ASXL3 nonsense variant plus a paternally inherited (asymptomatic father) 15q11.2 BP1-BP2 microdeletion, with "severe global developmental delay, hypotonia, feeding difficulties, microcephaly and recurrent respiratory infections"; authors propose "multilocus pathogenic variation can generate a blended, severe phenotype" with "convergence at the pathway rather than the complex level." n=1 — hypothesis-generating.
• Unidentified modifiers. PMID:42494517: "The family reports emphasize the possibility of additional, yet currently unidentified, factors influencing phenotypic expression."
• Thyroid hormone axis genes (DIO3, THRA) — mechanistic modifier candidates from the mouse model (§6.1).

4.4 Epigenetic information

ASXL3 is itself an epigenetic regulator (§6), so "epigenetic information" here has two senses.

(a) Downstream chromatin consequence. Elevated H2AK119Ub1 in patient fibroblasts (PMID:26647312) — the direct chromatin readout of PR-DUB dysfunction.

(b) DNA methylation episignature — a striking NEGATIVE result. This is an important, curation-worthy finding. Awamleh et al. (PMID:35361921, EJHG 2022) developed a blood DNAm signature for Bohring-Opitz syndrome and tested it on ASXL2 and ASXL3:

"We identified 763 differentially methylated CpG sites in individuals with BOS. Differentially methylated sites overlapped 323 unique genes, including HOXA5 and HOXB4… The DNAm profile of one individual with the ASXL2 variant was BOS-like, whereas the DNAm profiles of three individuals with ASXL3 variants were control-like. We also used Horvath's epigenetic clock, which showed acceleration in DNAm age in individuals with pathogenic ASXL1 variants, and the individual with the pathogenic ASXL2 variant, but not in individuals with ASXL3 variants."

Implications: (i) there is currently no validated BRPS episignature and the BOS classifier cannot be used to interpret ASXL3 VUS; (ii) ASXL3 dysfunction is mechanistically divergent from ASXL1 despite paralogy — consistent with the distinct clinical syndromes; (iii) no epigenetic age acceleration in BRPS. n=3 ASXL3 individuals — a dedicated, adequately powered BRPS episignature study is a clear knowledge gap.

(c) Regulation of ASXL3 itself. PMID:38791157 (Int J Mol Sci 2024, ASXL-family review): "Their expression is commonly regulated by DNA methylation at CpG islands preceding transcription starting sites." The same review notes "non-coding RNAs have been identified following mutations in the ASXL1 or ASXL3 gene."

4.5 Chromosomal abnormalities

Whole-gene or multi-exon deletions of ASXL3 are rare (GeneReviews: gene-targeted del/dup analysis detects 1–2%; CMA rarely). ClinGen notes "genomic copy-number variations causing haploinsufficiency in Bainbridge-Ropers syndrome patients have not yet been reported" as of the 2017 dosage curation — so 18q12.1 deletion patients are under-described relative to what pLI 1.00 predicts. Triplosensitivity score 0 — "At this time there is no evidence that supports the triplosensitivity of ASXL3."

No recurrent translocation, inversion, or aneuploidy mechanism.

5. Environmental Information

Environmental factors: None. BRPS is a fully penetrant-at-the-molecular-level Mendelian disorder; there is no documented toxin, radiation, pollution, or occupational contribution to causation. No entries in CTD linking environmental chemicals to ASXL3-mediated BRPS pathogenesis.

Lifestyle factors: Not applicable to causation. Relevant to management: nutritional intake (failure to thrive early, obesity risk later per PMID:40552904), sleep hygiene (sleep disturbance in 71% per PMID:34086428), and physical activity/rehabilitation (PMID:42111080).

Infectious agents: Not applicable to causation. Recurrent infections are reported as a secondary complication (HP:0002719, 1/3; recurrent respiratory infections in PMID:41458212), plausibly secondary to hypotonia, aspiration, and feeding difficulty rather than intrinsic immunodeficiency. No primary immunodeficiency has been characterized in BRPS — evidence gap.

One indirect environmental/nutritional lead: the mouse thyroid-hormone axis (§6.1) implies early-life thyroid hormone availability could be a modifiable environmental variable — entirely unvalidated in humans.

6. Mechanism / Pathophysiology

6.1 The causal chain

Node 1 — Molecular scale: heterozygous ASXL3 loss-of-function variant → reduced ASXL3 protein dosage

De novo truncating variant in exon 11 or 12 → NMD of the mutant transcript (MCR1/NMD class) or production of a truncated protein (MCR2/no-NMD class).

Evidence (PMID:26647312, IN_VITRO, patient fibroblasts):

"ASXL3 mRNA transcripts from the mutated allele are prone to nonsense-mediated decay, and expression of ASXL3 is reduced."

Suggested annotations: biological_scale: MOLECULAR; GO:0000184 nuclear-transcribed mRNA catabolic process, nonsense-mediated decay [verify].

Node 2 — Molecular scale: impaired PR-DUB (Polycomb Repressive Deubiquitinase) complex function

ASXL3 is a non-catalytic scaffolding subunit of PR-DUB, pairing with the deubiquitinase BAP1. Loss of ASXL3 impairs BAP1-mediated removal of monoubiquitin from histone H2A lysine 119.

Evidence (PMID:26647312):

"We found that ASXL3 interacts with BAP1, a hydrolase that removes mono-ubiquitin from histone H2A lysine 119 (H2AK119Ub1) as a component of the Polycomb repressive deubiquitination (PR-DUB) complex."

UniProt Q9C0F0 confirms: "Core component of the PR-DUB complex containing BAP1, ASXL proteins, and MBD proteins"; interacts with FOXK1, FOXK2, KDM1B, HCFC1, OGT.

Annotations: GO:0035517 PR-DUB complex [OLS-checked]; GO:0140950 histone H2A deubiquitinase activity [OLS-checked]; GO:0016578 histone deubiquitination [verify]; biological_scale: MOLECULAR.

Node 3 — Molecular scale: increased H2AK119 monoubiquitination (aberrant chromatin state)

Evidence (PMID:26647312, IN_VITRO):

"A significant increase in H2AK119Ub1 was observed in ASXL3 patient fibroblasts, highlighting an important functional role for ASXL3 in PR-DUB mediated deubiquitination." "This is the first single gene disorder linked to defects in deubiquitination of H2AK119Ub1…"

Annotations: GO:0000122 negative regulation of transcription by RNA polymerase II [verify]; GO:0006325 chromatin organization [verify]; GO:0005634 nucleus (CC) [verify]; biological_scale: MOLECULAR.

Node 4 — Molecular/cellular scale: genome-wide transcriptional dysregulation

Evidence (PMID:26647312, IN_VITRO):

"Out of 564 significantly differentially expressed genes (DEGs) in ASXL3 patient fibroblasts, 52% were upregulated and 48% downregulated. DEGs were enriched in molecular processes impacting transcriptional regulation, development and proliferation, consistent with the features of BRS."

Note the roughly symmetric up/down split — consistent with a chromatin scaffold whose loss both derepresses Polycomb targets and destabilizes activation, not a pure repressor.

Broader chromatin context (PMID:38791157): ASXL proteins act "through interactions with chromatin regulators (PRC2, TrxG, PR-DUB, SRC1, HP1α, and BET proteins) and with transcription factors, including nuclear hormone receptors (RAR, PPAR, ER, and LXR)", with associated marks including "histone H3K9 acetylation and methylation, H3K4 methylation, H3K27 methylation, and H2AK119 deubiquitination." The nuclear-hormone-receptor arm is mechanistically prescient given Node 5.

Node 5 — Molecular scale (novel, MODEL_ORGANISM): DIO3 derepression → brain thyroid hormone depletion

This is the single most important new mechanistic result and the first specific, druggable node in BRPS. bioRxiv preprint PPR1237608 (2026), Ding, Yuan, Hu, Zhang, Wu, Du, Qiu — "An ASXL3–thyroid hormone axis in parvalbumin interneurons controls autism-like behaviors":

"Mechanistically, Asxl3 loss derepresses the thyroid hormone (TH)–inactivating enzyme DIO3 via altered histone H2A monoubiquitination, depleting brain TH."

Preprint caveat: not yet peer-reviewed. Flag accordingly if curated; consider evidence_source: MODEL_ORGANISM and a HUMAN_MODEL_MISMATCH discussion node.

Annotations: CHEBI:60311 thyroid hormone [OLS-checked]; GO:0042403 thyroid hormone metabolic process [verify]; biological_scale: MOLECULAR.

Node 6 — Cellular scale: disrupted neural cell-fate specification and cortical development

Two independent model systems converge here.

Xenopus laevis (PMID:32132929, MODEL_ORGANISM):

"We have found that ASXL3 protein knockdown during early embryo development highly perturbs neural cell fate specification, potentially resembling the Bainbridge-Ropers syndrome phenotype in humans." "Dynamic chromatin modifications play important roles in the specification of cell fates during early neural patterning and development."

Mouse Asxl3^+/− (PPR1237608):

"Asxl3 haploinsufficiency in mice reduces cortical thickness and upper-layer projection neurons while increasing parvalbumin (PV) interneuron density and producing ASD-like behavioral abnormalities."

Annotations: GO:0021895 cerebral cortex neuron differentiation [verify]; GO:0030182 neuron differentiation [verify]; GO:0007399 nervous system development [verify]. Cell types: CL:4023018 pvalb GABAergic interneuron [OLS-checked]; CL:0011001 spinal cord motor neuron (not applicable); use CL:0000679 glutamatergic neuron [verify] and CL:0000099 interneuron [verify] for the projection-neuron/interneuron pair. biological_scale: CELLULAR.

Node 7 — Cellular/tissue scale: excitation–inhibition imbalance via PV interneuron expansion

PPR1237608 establishes causality through a receptor-conditional knockout:

"Conditional deletion of the TH receptor Thra in inhibitory neuron progenitors phenocopies the PV interneuron expansion, linking impaired TH signaling to PV circuit remodeling."

Annotations: GO:0051966 regulation of synaptic transmission, glutamatergic [verify]; GO:0060079 excitatory postsynaptic potential [verify]. biological_scale: CELLULAR.

Node 8 — Organism scale: neurodevelopmental phenotype

Cortical thinning + PV interneuron expansion + E/I imbalance → developmental delay, ID, absent speech, ASD, hypotonia, seizures. In humans, cortical/structural correlates are often subtle or absent — GeneReviews notes seizures occur with "most have normal brain MRI imaging" — but where imaging is abnormal the findings are: thin corpus callosum, widened frontal subarachnoid space, deepened sulci (PMID:32517662); cerebellar vermis hypoplasia, ventriculomegaly (HPO); prominence of the Sylvian fissure with bitemporal hollowing (PMID:29445472); pontocerebellar hypoplasia type 1 in a fetus (PMID:29316359); progressive cerebral/cerebellar atrophy in a severe case (PMID:35172777).

Parallel branch — cardiomyocyte proliferation/apoptosis (biallelic missense, congenital heart disease)

Distinct from the dominant BRPS mechanism. PMID:37435360 (Biochem Biophys Rep 2023, IN_VITRO/MODEL_ORGANISM, mouse cardiomyocytes): compound heterozygous ASXL3 mutations "inhibited the proliferation of cardiomyocytes and accelerated cell apoptosis by promoting the expression of lncRNAs," via lncRNA NONMMUT063967.2 → suppression of FGFR2 → inhibition of Ras/ERK signaling; "suppression of lncRNA NONMMUT063967.2 and overexpression of FGFR2 reversed the effects." This corresponds to the GeneReviews note about biallelic missense variants in four individuals with congenital heart defects. Treat as a separate, provisional allelic mechanism, not part of the BRPS pathograph.

6.2 Upstream vs downstream summary

6.3 Other mechanism dimensions

• Protein dysfunction. UniProt Q9C0F0: 2,248 aa; HTH HARE-type domain (aa 10–84), DEUBAD domain (aa 254–363) — the BAP1-binding module — and an atypical PHD-type zinc finger (aa 2,210–2,247). Note that MCR1 (c.1095_2237 ≈ aa 365–746) lies immediately C-terminal to the DEUBAD domain, while MCR2 (c.3043_4906 ≈ aa 1015–1635) is mid-protein; both classes of truncation remove the C-terminal PHD finger, which is a plausible structural explanation for the shared core phenotype. Mechanism: loss of function (GeneReviews).
• Metabolic changes. No classic metabolic derangement. The only metabolic axis implicated is thyroid hormone inactivation via DIO3 (mouse only). No routine metabolic screen abnormality is described in BRPS.
• Immune system involvement. None established. Recurrent infections are likely secondary (aspiration/hypotonia). Evidence gap.
• Tissue damage mechanisms. BRPS is a developmental/patterning disorder, not a degenerative or injury-driven one. No oxidative stress, ischemia, fibrosis, or necrosis mechanism is described. The occasional reports of progressive atrophy are unexplained outliers.
• Biochemical abnormalities. No enzyme deficiency, receptor defect, or channelopathy. No diagnostic biomarker.
• Molecular profiling.
• Transcriptomics: 564 DEGs in patient fibroblasts, 52% up / 48% down (PMID:26647312). Cortical transcriptomics in mouse (PPR1237608).
• Proteomics: none for BRPS — gap.
• Metabolomics / lipidomics: none — gap.
• Epigenomics: H2AK119Ub1 ChIP in fibroblasts (PMID:26647312); blood DNAm profiling with no BRPS-specific signature (PMID:35361921).
• Single-cell / spatial: none published for BRPS specifically — gap. PV-interneuron density quantification in mouse (PPR1237608) is the closest.
• Functional genomics screens: no BRPS-directed CRISPR/RNAi screen — gap.
• Expression pattern. Human Protein Atlas: low tissue specificity (tau 0.66), with the strongest signal in testis-associated clusters; brain-region RNA data sparse; highest single-cell signal in pituitary stem cells. GeneReviews states ASXL3 is "expressed in similar tissues to ASXL1 including brain, spinal cord, kidney, liver, and bone marrow, but at a lower level." MGI GXD records 608 assay results across 9 tissues with embryonic expression across nervous, cardiovascular, musculoskeletal and reproductive systems. Note the tension: bulk adult-tissue data understate brain expression, while the developmental and model data place the critical requirement in the embryonic/fetal brain. Chromatin regulators binding "primarily during fetal development" (PMID:42111080).

7. Anatomical Structures Affected

7.1 Organ level

Primary: central nervous system — cerebral cortex (thinning, reduced upper-layer projection neurons), corpus callosum (thin/hypoplastic), cerebellum (vermis hypoplasia; pontocerebellar hypoplasia in a fetal case), ventricular system (dilatation).

Body systems involved:

Secondary/complication organs: lung (aspiration), esophagus (reflux esophagitis), spine (neuromuscular scoliosis), skin (self-injury sequelae).

UBERON suggestions [all verify]: UBERON:0000955 brain; UBERON:0000956 cerebral cortex; UBERON:0002336 corpus callosum; UBERON:0002037 cerebellum; UBERON:0004720 cerebellar vermis; UBERON:0002240 spinal cord; UBERON:0001004 respiratory system; UBERON:0001007 digestive system; UBERON:0002113 kidney; UBERON:0000970 eye; UBERON:0001456 face; UBERON:0001474 bone element.

7.2 Tissue and cell level

Tissues: nervous tissue (cerebral cortical grey matter, white matter tracts, cerebellar cortex); skeletal muscle (secondarily, via central hypotonia — muscle biopsy is not characteristically abnormal); connective tissue (joint laxity); oral mucosa/gingiva.

Cell populations (CL): - CL:4023018 pvalb GABAergic interneuron [OLS-checked] — expanded in Asxl3^+/− mouse cortex; the central cellular node of the new mechanism. (Human-specific alternative: CL:4072029 pvalb GABAergic interneuron (Homo sapiens) [OLS-checked]; related: CL:0020071 parvalbumin-positive basket cell [OLS-checked].) - Cortical upper-layer projection (glutamatergic) neurons — reduced. CL:0000679 glutamatergic neuron [verify]; CL:0011005 GABAergic interneuron [verify]. - Neural progenitor / neural stem cells — cell-fate specification perturbed (Xenopus). CL:0011020 neural progenitor cell [verify]. - Cardiomyocyte — CL:0000746 cardiac muscle cell [verify] (biallelic-missense branch only). - Dermal fibroblast — the principal ex vivo experimental cell type (CL:0000057 fibroblast [verify]); not a disease-affected cell type per se.

7.3 Subcellular level

• Nucleus — GO:0005634 [verify]; the site of all ASXL3 function.
• Chromatin / nucleosome — GO:0000785 chromatin [verify].
• PR-DUB complex — GO:0035517 [OLS-checked] (the most specific and best-supported cellular-component annotation for ASXL3).

7.4 Localization and lateralization

CNS involvement is bilateral and diffuse/symmetric. Craniofacial features are symmetric. Ulnar deviation and contractures are typically bilateral. One reported dextrocardia (situs abnormality) is a laterality exception in a single patient (PMID:41659201) — do not generalize.

8. Temporal Development

Onset - Prenatal (fetal): IUGR ~35% (PMID:39833101); polyhydramnios; breech presentation; arthrogryposis; pontocerebellar hypoplasia detectable at fetopathology (PMID:29316359). "An increased prevalence of antenatal and neonatal structural anomalies" (PMID:40552904). - Neonatal/infantile: hypotonia, feeding difficulty, failure to thrive — the presenting complaint in most. Caesarean delivery 9/12 (HPO). - Early childhood: developmental delay recognized; absent/limited speech; autistic features; strabismus. - Childhood: seizure onset — "All three had childhood-onset generalized epilepsy" (PMID:29367179). - Adolescence/adulthood: behavioral escalation; possible obesity; pubertal timing questions; rare late-onset feeding decline (PMID:38711055); rare adult diagnosis (a 28-year-old first diagnosed, PMID:39698206).

Onset pattern: congenital, insidious. Not acute.

Progression - Rate: slow; substantially non-progressive/static with improvement in core domains. PMID:40552904: "improvement trends in feeding, hypotonia, verbalisation, and motor skills over time." - Stages: no formal staging system exists. A pragmatic natural-history framing from the literature: (1) infantile — feeding/hypotonia/FTT dominate; (2) early childhood — developmental and communication deficits dominate, seizures may appear; (3) school-age/adolescent — behavior, sleep, motor/orthopedic and dental issues dominate, feeding often improves; (4) adult — behavioral/psychiatric management, mobility and contracture management. - Course: chronic, lifelong; not relapsing-remitting; seizures and breath-holding are episodic. - Divergent trajectories: hypotonia→spasticity/contracture conversion; rare progressive atrophy.

Remission patterns: No spontaneous remission of the core disorder. Symptom-level remission is achievable: near-complete remission of self-aggression with pregabalin (PMID:39698206); behavioral reduction of self-injury with ABA (PMID:36249891); feeding independence is often regained.

Critical periods (intervention windows) - Neonatal/infantile feeding window — early feeding therapy and timely G-tube placement determine growth trajectory. - Early intervention 0–3 years — GeneReviews-recommended; standard for DD/ID. - A biologically defined neonatal window in the mouse model — PPR1237608: "Neonatal, but not adolescent, TH supplementation restores PV interneuron numbers and rescues behavior in Asxl3 +/− mice, defining a critical early window for intervention." If translatable, this would be the most consequential finding in the field. Currently MODEL_ORGANISM only.

9. Inheritance and Population

9.1 Epidemiology

• Prevalence: unknown. GeneReviews: "The prevalence of ASXL3-related disorder is not known. However, to date ASXL3 is one of the top ten genes in which pathogenic variants have been found in large-scale exome sequencing studies of individuals with ID."
• Orphanet (ORPHA:352577, via Orphadata API):
• Point prevalence, class <1 / 1 000 000, Worldwide, Validated → in dismech terms: measure_type: POINT_PREVALENCE, prevalence_class: BELOW_1_IN_1000000, rate_per_100000: <0.1.
• Cases/families: 77, Worldwide, Validated (measure_type: CASES_IN_LITERATURE), sourced to PMID:28955728. This is now clearly out of date.
• Published case count over time (a useful ascertainment curve): 4 (2013, PMID:23383720) → 9 (2016, PMID:27901041) → 27 (2017, PMID:28955728) → 29–33 (2018–2021, PMID:29316359, PMID:33242595) → 45 new + literature (2021, PMID:34436830) → 64 (2025 NHS, PMID:40552904) → 204 individuals in the 2026 literature review (PMID:42494517). Note PMID:40237215 (2025) still cites "only 45 cases" — the literature is inconsistent; prefer the 2026 figure.
• Incidence: no published estimate. Gap.
• Relative diagnostic yield: ASXL3 recurs in ID/ASD/DD exome cohorts (DDD, DECIPHER, ASC). PMID:28100473 notes the condition's "surprisingly high frequency." SFARI: exome-wide significance for ASD in Zhou et al. 2022 (42,607 ASD cases, P < 2.5E-06).

Curation recommendation: record Orphanet's BELOW_1_IN_1000000 point-prevalence class with a note that it is likely an underestimate driven by ascertainment, and record CASES_IN_LITERATURE: 204 from PMID:42494517 as the current best count.

9.2 Inheritance

• Mode: Autosomal dominant (HP:0000006; HPO-annotated for OMIM:615485). GeneReviews: "ASXL3-related disorder is an autosomal dominant disorder typically caused by a de novo pathogenic variant."
• De novo fraction: the large majority. PMID:29429203's literature review found "31 variations in ASXL3 gene…all de novo variations."
• Penetrance: GeneReviews has no Penetrance heading (confirmed on direct retrieval). Penetrance is therefore formally not established; multiple sources discuss reduced penetrance and nonpenetrance in inherited-variant families (PMID:34436830; PMID:42494517; PMID:33242595 on LoF in healthy individuals). This is a genuine and important knowledge gap — flag for a KNOWLEDGE_GAP discussion node.
• Expressivity: highly variable, including intrafamilial. PMID:36177608: "This report demonstrates intrafamilial phenotypic heterogeneity and confirms heritability of ASXL3-related disorder."
• Genetic anticipation: not applicable (no repeat expansion). No evidence.
• Germline / parental mosaicism: Established and clinically important. GeneReviews documents germline mosaicism in three families. Directly demonstrated: paternal mosaicism at 8.17% blood VAF / 15.03% semen VAF (PMID:40980137); maternal mosaicism ~15% blood VAF transmitted to two half-brothers (PMID:42194125); parental mosaicism causing non-twin sibling recurrence in the Spanish cohort (PMID:39833101); presumed de novo variant shared by siblings (PMID:29305346).
• Founder effects: none identified. Recurrent variants (p.Arg1444*, p.Arg1560*) reflect mutational hotspots (likely CpG transitions), not founders.
• Consanguinity: irrelevant for the dominant disorder. Potentially relevant only for the unproven biallelic-missense/CHD branch.
• Carrier frequency: not applicable (dominant, de novo). Population carrier frequency of pathogenic ASXL3 PTVs is effectively zero (pLI 1.00).

Recurrence risk counseling (from GeneReviews): - Parent carries the variant → 50% to each sib. - Variant undetectable in parental leukocyte DNA → "recurrence risk to sibs is slightly greater than that of the general population because of the possibility of parental germline mosaicism." - Offspring of an affected individual → 50%. - PMID:40980137 argues for upgrading this: "This study establishes parental chimerism as an important genetic mechanism for ASXL3-associated disorders and emphasizes the need for ultrasensitive testing in genetic counseling."

9.3 Population demographics

• Ethnicity/ancestry: GeneReviews — affected individuals reported "across all ethnicities," with ascertainment concentrated in countries performing genomic testing. Published cohorts: UK/DDD (PMID:28100473, PMID:34436830), Germany/Europe (PMID:27901041), Spain n=22 (PMID:39833101), multiple Chinese cohorts (PMID:41659201, PMID:39610869, PMID:32517662, PMID:35276034), Japan (PMID:29445472, PMID:38711055), Turkey (PMID:40237215), Sudan (PMID:34886823), India (PMID:31638014), USA, Switzerland, Slovakia.
• Geographic distribution: worldwide; no endemic focus. Apparent regional clustering reflects genomic-testing access, not biology.
• Variant geography: no ancestry-specific variants. PMID:41659201 and PMID:39610869 both suggest "subtle distinctions in clinical manifestations between Chinese patients and other racial groups" — likely ascertainment/reporting differences; treat cautiously.
• Sex ratio: no significant skew reported. Individual series are small and mixed (PMID:34086428: 5 males, 2 females). No formal sex-ratio analysis published — gap.
• Age distribution: cohorts are predominantly pediatric, reflecting ascertainment via developmental-disorder testing. Adults are increasingly recognized (28- and 30-year-olds in PMID:39698206; late-onset epilepsy in an older adult male, PMID:29628764). One HPO-annotated "death in infancy" (1/4) at the severe end.

10. Diagnostics

10.1 Genetic testing — the definitive modality

GeneReviews: "The diagnosis of ASXL3-related disorder is established in a proband by identification of a heterozygous pathogenic (or likely pathogenic) variant in ASXL3 by molecular genetic testing."

Recommended approach (GeneReviews): 1. Chromosomal microarray (CMA) first-line, to detect large deletions/duplications (rarely identifies ASXL3 variants but is standard-of-care for undiagnosed DD/ID). 2. Intellectual disability multigene panel or exome sequencing if CMA nondiagnostic. 3. Trio-based exome sequencing is the workhorse in practice — used in essentially every published cohort (PMID:28100473, PMID:39610869, PMID:41659201, PMID:40980137).

Detection rates: sequence analysis 98–99%; gene-targeted deletion/duplication analysis 1–2%; CMA rarely.

Other modalities: - Whole genome sequencing (WGS): used in the founding study (PMID:23383720). Adds value for splice/deep-intronic/structural variants; no BRPS-specific WGS yield data. - Single-gene testing: appropriate only for targeted familial-variant testing or prenatal/cascade testing. - Sanger sequencing: confirmatory and for segregation analysis (universal in published reports). - Ultra-deep / targeted deep sequencing of parental DNA (blood ± semen): newly recommended when a variant appears de novo but the family wants accurate recurrence-risk counseling (PMID:40980137, PMID:42194125). This is an actionable practice change. - Karyotyping, FISH, mtDNA testing, repeat-expansion testing: not indicated for BRPS.

10.2 Omics-based diagnostics

• DNA methylation episignature: NOT available for BRPS. "the DNAm profiles of three individuals with ASXL3 variants were control-like" (PMID:35361921). Do not use the BOS classifier for ASXL3 VUS. This is a real diagnostic gap for missense/VUS interpretation.
• RNA sequencing: not established diagnostically. Research-only demonstration of NMD and 564 DEGs in fibroblasts (PMID:26647312). RNA-seq could in principle confirm NMD for splice VUS.
• Proteomics, metabolomics, liquid biopsy: none. Not applicable.

10.3 Clinical, laboratory, imaging, and functional tests

• Laboratory tests / biomarkers: none. There is no diagnostic or prognostic biomarker for BRPS. Labs are used for supportive management (nutritional status, growth) only.
• Imaging: Brain MRI — most individuals have normal imaging even with seizures (GeneReviews). When abnormal: thin corpus callosum, widened frontal subarachnoid space, deep sulci (PMID:32517662); ventriculomegaly; cerebellar vermis hypoplasia; prominence of the Sylvian fissure with bitemporal hollowing (PMID:29445472); pontocerebellar hypoplasia (fetal, PMID:29316359). Renal ultrasound is now recommended at baseline (PMID:40552904). Spine radiography for scoliosis. Prenatal ultrasound may show IUGR/arthrogryposis.
• Electrophysiology — EEG: the most informative functional test. PMID:29367179:

  "EEG typically showed features consistent with generalized epilepsy including generalized spike-wave, photoparoxysmal response, and occipital intermittent rhythmic epileptiform activity." Critically, breath-holding/dystonic episodes are non-epileptic: "frequent episodes of breath-holding accompanied by dystonic posturing… without ictal EEG correlate" (PMID:35172777). Video-EEG is therefore essential to avoid over-treatment with anti-seizure medication.

• Functional/motor assessment: quantitative gait analysis + neurological examination + developmental questionnaires (PMID:38027485); a proposed structured neuromotor assessment framework borrowed from cerebral palsy and spina bifida (PMID:42111080).
• Other functional: sleep study (polysomnography) for sleep apnea; swallow study / videofluoroscopy for aspiration risk; formal ophthalmologic and dental evaluation; audiology as part of DD workup.
• Biopsy / histopathology: no diagnostic role. Skin biopsy fibroblasts are used for research only. Fetal neuropathology contributed to one prenatal case (PMID:29316359).

10.4 Clinical criteria and differential diagnosis

Suggestive findings (GeneReviews): DD/ID (typically moderate-to-severe) plus any of — speech/language delay or absent speech; ASD or autistic traits; the dysmorphic gestalt (prominent forehead, highly arched eyebrows, synophrys, widely spaced eyes, downslanted palpebral fissures, long tubular nose, wide mouth with full everted lower lip, crowded teeth); feeding difficulties; hypotonia; poor postnatal growth; epilepsy (GTCS and absence); vision impairment/strabismus; skeletal abnormalities (Marfanoid habitus, pectus excavatum, scoliosis, arachnodactyly, joint contractures).

There is no consensus clinical diagnostic criteria set (no DSM/ICD/society criteria); diagnosis is molecular.

Differential diagnosis — the key discriminations:

10.5 Screening

• Newborn screening: not applicable — no biochemical marker; not on any NBS panel.
• Carrier screening: not applicable (dominant, de novo).
• Cascade screening: applicable once a familial variant is identified, especially given documented inherited variants and mildly affected/nonpenetrant relatives.
• Parental ultra-deep sequencing (blood ± semen) after an apparently de novo diagnosis — an emerging recommendation (PMID:40980137).
• Prenatal diagnosis: amniocentesis with targeted variant testing once the familial variant is known (successfully applied at 18 weeks in PMID:40980137). PMID:36317208 reports prenatal diagnosis for a Chinese BRPS pedigree.

11. Outcome / Prognosis

Survival and mortality - No survival curve, 5-/10-year survival, or life-expectancy estimate exists for BRPS. Major evidence gap. - HPO annotates HP:0001522 Death in infancy at 1/4 in one small early series — this reflects severe-end ascertainment and should not be read as a general infant mortality rate. - Long-term survival to adulthood is clearly the norm in more recent series: patients diagnosed at 28 and managed at 30 (PMID:39698206); an older adult male with late-onset epilepsy (PMID:29628764); the 2025 NHS cohort spans a wide age range (PMID:40552904). - Mortality risk is presumably driven by aspiration, respiratory compromise, refractory seizures, and severe feeding failure — plausible but not quantified.

Morbidity and function - Morbidity is high and lifelong: near-universal ID with absent/limited speech means most individuals require substantial lifelong support. - 100% of assessed individuals met criteria for developmental coordination disorder (PMID:38027485). - Motor: ranges from independent ambulation to inability to walk (HP:0002540, 1/4). - No BRPS-specific ICF/disability or QoL instrument data — gap.

Disease course / complications - Aspiration pneumonia and respiratory infections; GERD and esophagitis; failure to thrive then possible obesity; neuromuscular scoliosis and contractures; refractory epilepsy in a minority; refractory breath-holding spells; severe self-injury and aggression; sleep apnea; dental disease; strabismus/amblyopia; emerging renal involvement. - Single reported precursor B-ALL (PMID:35733401) — not an established complication.

Recovery potential - No cure; the underlying developmental lesion is not reversible with current therapy. - Meaningful functional gains are documented and should be communicated to families: "improvement trends in feeding, hypotonia, verbalisation, and motor skills over time" (PMID:40552904). Many children wean off tube feeding. - Behavioral symptoms can respond dramatically to targeted intervention (PMID:39698206, PMID:36249891).

Prognostic factors - Variant class and location are the best-supported prognostic markers: NMD-predicted variants and MCR1 (exon 11) variants associate with more severe ID/GDD, more microcephaly, more sleep apnea, more hyperventilation, and more feeding-tube use; MCR2 (exon 12) / no-NMD associate with more formal autism diagnoses and more perinatal feeding problems (PMID:42494517; PMID:39833101). - Presence of refractory seizures or refractory breath-holding spells marks a severe phenotype (PMID:35172777). - Age is favorable — older individuals do better in feeding, tone, motor and verbal domains. - Prognostic biomarkers: none.

12. Treatment

There is no disease-modifying therapy. Management is entirely symptomatic, supportive, and multidisciplinary, per GeneReviews.

12.1 Supportive and rehabilitative care (the mainstay)

A structured, CP/spina-bifida-derived neuromotor assessment-and-management framework is proposed in PMID:42111080 — the first BRPS-specific rehabilitation protocol proposal, though it is a perspective paper, not a trial.

12.2 Pharmacotherapy

Anti-seizure medications. Standard management by a neurologist for childhood-onset generalized epilepsy with GTCS ± atypical absence (PMID:29367179). Given the generalized phenotype, broad-spectrum agents (valproate, levetiracetam, lamotrigine) are the rational choice; note there are no BRPS-specific ASM efficacy data. Encoding: treatment_term NCIT:C15986 Pharmacotherapy + therapeutic_agent CHEBI term per agent [verify].

Pregabalin for severe challenging behavior — a notable single-case success. PMID:39698206 (Front Psychiatry 2024), a 30-year-old with BRPS, severe ID, ASD and epilepsy admitted for self-aggression, agitation, hetero-aggression and mood change:

"The introduction of Pregabalin leads to rapid stabilization of the clinical state, almost complete improvement in challenging behavior and gradual withdrawal of other treatments (class 2 analgesics, neuroleptics, antidepressants, and benzodiazepines). At the neurological check-up 9 months after discharge from hospital, clinical stability was confirmed… with almost complete disappearance of auto-aggressive gestures." Encoding: treatment_term NCIT:C15986 Pharmacotherapy; therapeutic_agent CHEBI:64356 pregabalin [OLS-checked]; therapeutic_modality: SMALL_MOLECULE. n=1 — curate with appropriate evidence weighting.

Failed pharmacotherapy — worth recording as negative evidence. Refractory breath-holding spells did not respond to iron supplementation, acetazolamide, or desipramine (PMID:35172777). Suitable for supports: REFUTE / NO_EVIDENCE evidence items.

Psychotropics generally. Standard management of ADHD, aggression, self-injury, and sleep disturbance; PMID:34086428 documents the high psychiatric comorbidity burden requiring this. No BRPS-specific evidence base.

Pharmacogenomics: none specific to BRPS.

12.3 Advanced therapeutics — preclinical only

AAV-delivered split-intein ASXL3 gene replacement — the most advanced therapeutic concept. From bioRxiv PPR1237608 (2026):

"An intein-based AAV system that reconstitutes full-length ASXL3 normalizes cortical architecture and behavior in Asxl3 +/− mice and drives efficient ASXL3 expression in non-human primate brain, establishing an ASXL3–TH–PV interneuron axis as a targetable pathway in ASD."

This solves the central obstacle for ASXL3 gene therapy — the 2,248-aa coding sequence far exceeds AAV packaging capacity — by splitting the transgene across two vectors and reconstituting the protein via split inteins. NHP expression data raise translational plausibility. Encoding if curated: therapeutic_modality: GENE_THERAPY; NCIT:C15238 Gene Therapy [verify]. Status: preprint, mouse + NHP expression only. No human data.

Neonatal thyroid hormone supplementation. Same preprint: rescues PV interneuron numbers and behaviour in Asxl3^+/− mice when given neonatally but not in adolescence. Potentially repurposable (levothyroxine/liothyronine are approved, cheap, and safe) — but the target is brain TH depletion via DIO3, and whether systemic supplementation reaches the brain compartment in humans, and whether a comparable window exists postnatally in humans, is unknown. Do not present as a clinical option. Suggested CHEBI: CHEBI:60311 thyroid hormone [OLS-checked]; specific agents (levothyroxine, liothyronine) [verify].

Cell therapy, ASO, siRNA, mRNA, gene editing, immunotherapy, targeted small molecules: none reported. Note that ASO/siRNA knockdown strategies are conceptually inapplicable to a haploinsufficiency disorder; upregulation approaches (TANGO-style, CRISPRa) would be the logical modality and have not been attempted.

12.4 Behavioral intervention (best-evidenced non-pharmacologic modality for behavior)

PMID:36249891 (Behav Anal Pract 2023) — first published behavioral treatment in BRPS:

"There are no published treatments for BRPS. We targeted self-injury in a child with BRPS using a functional analysis and differential reinforcement, with several extensions to common procedures. Results present the first example of behavioral reduction for self-injury in BRPS. • ABA strategies can reduce self-injury in BRPS • Evaluating multiply maintained self-injury following identification of an automatic function is important. • Sleep deficits may complicate assessment."

Encoding: therapeutic_modality: BEHAVIORAL; NCIT:C181743 Behavioral Counseling [verify] (note: OLS search for "applied behavior analysis" returned only NCIT:C204364 Behavioral Analyst, a role term, not an intervention — do not use it as a treatment_term).

12.5 Surgical / interventional

Gastrostomy; Nissen fundoplication for severe GERD; orthopedic surgery for contractures/scoliosis; strabismus surgery; ENT/airway surgery for laryngomalacia or obstructive sleep apnea. All standard-of-care, none BRPS-specific.

12.6 Experimental treatments / clinical trials

No interventional clinical trials in BRPS were identified. No NCT identifiers. The only registered study found is observational: the International ASXL3 Natural History Study (IRAS 316055) (PMID:40552904). This is a therapeutic desert and, given the AAV-intein preclinical result, a natural target for trial-readiness work (biomarker development, outcome-measure validation, patient registry expansion).

12.7 Treatment outcomes and strategy

• Response rates: not quantifiable — no controlled data. Anecdotal: pregabalin near-complete behavioral remission (n=1); ABA effective for self-injury (n=1); breath-holding refractory to three agents (n=1).
• Adverse events: no BRPS-specific safety signal. Standard agent-specific risks apply.
• Treatment algorithm: the GeneReviews evaluation/treatment/surveillance tables (§12.1, §13) constitute the de facto algorithm. PMID:40552904 adds two explicit new recommendations: "baseline renal imaging after diagnosis, and Dental and Ophthalmological follow-up for all."
• Personalized/genotype-guided treatment: none yet — but the MCR1/MCR2 and NMD/no-NMD stratification (PMID:42494517) is the natural substrate for genotype-guided surveillance intensity (e.g., prioritize sleep-apnea and microcephaly surveillance in NMD/MCR1; prioritize autism-specific supports in no-NMD/MCR2).

13. Prevention

Primary prevention: Not possible for de novo variants. The only genuine primary-prevention lever is reproductive: preimplantation genetic testing (PGT-M) or prenatal diagnosis for a family with a known variant — GeneReviews: "Once the ASXL3 pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible." No behavioral, dietary, vaccination, environmental, or public-health intervention prevents BRPS.

Secondary prevention (early detection): - No population or newborn screening. - Early trio-ES in infants with hypotonia + feeding difficulty + FTT + developmental delay is the practical secondary-prevention route, enabling early intervention. - Prenatal detection: possible via WES in fetuses with arthrogryposis / IUGR / PCH1-pattern findings (PMID:29316359); amniocentesis with targeted testing when a parental mosaic or affected-parent variant is known (PMID:40980137, PMID:36317208).

Tertiary prevention (preventing complications) — the highest-yield category. Per GeneReviews surveillance table plus 2025 additions:

Additional tertiary measures: aspiration precautions and timely gastrostomy; seizure action plan and caregiver education; AAC provision to reduce frustration-driven behavior; multidisciplinary dental prevention (PMID:40237215).

Genetic counseling: central. Must cover (i) 50% recurrence for a carrier parent, 50% for offspring of an affected individual; (ii) the elevated-above-background sib recurrence risk from germline mosaicism even when parental blood testing is negative; (iii) the case for ultra-deep parental sequencing including semen where feasible (PMID:40980137); (iv) the reality of variable expressivity and possible nonpenetrance in inherited-variant families, which complicates counseling of apparently unaffected relatives (PMID:42494517).

Immunization: routine schedule; no contraindication and no disease-specific vaccine. Not applicable.

Public health / environmental interventions: Not applicable.

Prophylaxis: No specific prophylactic medication. Aspiration and respiratory-infection prophylaxis is supportive.

14. Other Species / Natural Disease

Taxonomy of species with characterized ASXL3 orthologs used in disease research:

Orthologous genes: mouse Asxl3 (MGI:2685175, Chr 18, 22,477,303–22,663,072 bp, + strand, 11.96 cM) — direct ortholog of human ASXL3 (18q12.1). Xenopus laevis asxl3 — ortholog used for knockdown. The ASXL family (ASXL1/2/3) descends from Drosophila melanogaster Additional sex combs (Asx); PMID:38791157 notes "Genes in this family and their neighbor genes are evolutionary conserved in humans and mice."

Natural disease in other species: None reported. No OMIA entry, no naturally occurring ASXL3 disorder in companion animals or wildlife has been described. Veterinary relevance: none. (An incidental hit for canine gastrointestinal lymphoma somatic mutations, PMID:40046420, is unrelated to BRPS.)

Comparative pathology: BRPS-like phenotypes exist only in engineered models. Asxl3^+/− mice recapitulate the ASD-like behavior and cortical architectural changes but the full human syndrome (craniofacial gestalt, absent speech, feeding failure) is not modeled — see §15.

Evolutionary conservation of mechanism: strongly conserved. The Asx→ASXL1/2/3 lineage and the PR-DUB complex (Asx–Calypso in fly; ASXL–BAP1 in mammals) are deeply conserved, and H2AK119Ub1 regulation is a core metazoan chromatin mechanism. The Xenopus knockdown reproducing neural cell-fate perturbation is direct evidence of conserved developmental function across ~350 My of vertebrate divergence.

Transmission / zoonotic potential: Not applicable — non-communicable genetic disorder.

15. Model Organisms

15.1 Mouse (Mus musculus) — the principal model

Resources: MGI:2685175, Asxl3. 8 alleles available (3 endonuclease-mediated, 1 gene-trapped, 4 targeted); 97 strains/lines listed through IMSR. MGI records 13 phenotypes from multigenic genotypes and 11 phenotype references. GXD holds 608 expression assay results across 9 tissues with embryonic expression in nervous, cardiovascular, musculoskeletal and reproductive systems.

IMPC status (Data Release 24.0): Asxl3 has been phenotyped with 0 significant phenotypes across 15 of 24 physiological systems tested (9 systems untested); no adult or embryonic expression data recorded. This is an important negative: the standard IMPC broad-based pipeline does not detect the Asxl3 heterozygote phenotype — CNS/behavioral deep phenotyping is required, which is exactly what the 2026 study supplied.

The definitive model — Asxl3^+/− haploinsufficient mouse (bioRxiv PPR1237608, 2026; Ding, Yuan, Hu, Zhang, Wu, Du, Qiu): - Model type: germline heterozygous null — genetically faithful to the human dominant LoF mechanism (the correct design; homozygous nulls would model a non-existent human genotype). - Phenotype recapitulation: reduced cortical thickness; reduced upper-layer projection neurons; increased PV interneuron density; ASD-like behavioral abnormalities. Molecular: DIO3 derepression via altered H2A monoubiquitination → brain TH depletion. - Mechanistic validation: Thra conditional deletion in inhibitory neuron progenitors phenocopies the PV expansion. - Therapeutic validation: neonatal (not adolescent) TH supplementation rescues PV number and behavior; intein-based AAV reconstitution of full-length ASXL3 normalizes cortical architecture and behavior. - Limitations: does not model the craniofacial gestalt, feeding failure/FTT, absent speech (no analog), seizures (not reported), or the human MCR1/MCR2 and NMD/no-NMD distinction (a single null allele cannot capture the truncated-protein class). Preprint status.

Other mouse work: PMID:37435360 used mouse cardiomyocytes to model biallelic missense ASXL3 mutations and congenital heart disease — a different genotype and a different disease question; not a BRPS model. A closely relevant family model is Asxl1 loss in mice causing microcephaly via neural stem cell survival (PMID:40276524) — useful for comparative interpretation.

15.2 Xenopus laevis — developmental patterning model

PMID:32132929 (Front Physiol 2020, Lichtig et al.), MODEL_ORGANISM:

"In this study, we utilize the frog, Xenopus laevis as a simpler and more accessible vertebrate neurodevelopmental model system to understand the embryological cause of Bainbridge-Ropers syndrome. We have found that ASXL3 protein knockdown during early embryo development highly perturbs neural cell fate specification, potentially resembling the Bainbridge-Ropers syndrome phenotype in humans. Thus, the frog embryo is a powerful tool for understanding the etiology of Bainbridge-Ropers syndrome in humans."

• Model type: morpholino/protein knockdown in early embryos (not a genetic null; standard morpholino specificity caveats apply).
• Recapitulation: early neural cell-fate specification defects — captures the developmental patterning arm.
• Limitations: knockdown rather than heterozygous LoF; early embryonic window only; no behavioral, craniofacial-gestalt, or postnatal readouts; morpholino off-target risk.
• Applications: rapid screening of variant function; early neural patterning mechanism; potentially a variant-function assay for missense VUS interpretation (an unexploited opportunity given the absent episignature).

15.3 Cellular / in vitro models

• Patient-derived primary dermal fibroblasts — the workhorse for the founding mechanism (PMID:26647312): NMD demonstration, H2AK119Ub1 quantification, and RNA-seq (564 DEGs). Limitation: fibroblasts are not a disease-relevant cell type for a brain disorder, so the 564-DEG signature should not be over-interpreted as the neuronal program.
• iPSC-derived neurons / cortical organoids / neural progenitors: not reported for ASXL3 — a conspicuous gap. Given the PV-interneuron and upper-layer-projection-neuron findings in mouse, human iPSC-derived cortical and MGE-derived interneuron models are the obvious next step and would be the natural place for MorPhiC-style null-allele cellular phenotyping (category: Cellular, evidence_source: IN_VITRO). ASXL3 is not among the MorPhiC anchor genes (ISL1, EOMES, GCM1, NKX2-1).
• Mouse cardiomyocytes (PMID:37435360) — biallelic-missense/CHD branch only.

15.4 Model resources

MGI (informatics.jax.org, MGI:2685175); IMPC (mousephenotype.org, Data Release 24.0, CC BY 4.0); IMSR (97 Asxl3 lines); Xenbase; Alliance of Genome Resources.

Summary of Evidence Gaps (for KNOWLEDGE_GAP / HUMAN_MODEL_MISMATCH curation)

Sources

Primary literature (PubMed / Europe PMC) - PMID:23383720 — Bainbridge MN et al. Genome Med 2013 — founding description - PMID:24044690 — Dinwiddie DL et al. BMC Med Genomics 2013 - PMID:26647312 — Srivastava A et al. Hum Mol Genet 2016 — PR-DUB/H2AK119Ub1 mechanism - PMID:27901041 — Kuechler A et al. Eur J Hum Genet 2017 — recognizable condition; BOS distinction - PMID:28100473 — Balasubramanian M et al. J Med Genet 2017 — DDD cohort, second MCR - PMID:28955728 — Dad R et al. Neurol Genet 2017 — hyperventilation-athetosis - PMID:29316359 — Bacrot S et al. Birth Defects Res 2018 — first fetal case / PCH1 - PMID:29367179 — Myers KA et al. Epilepsy Res 2018 — childhood-onset generalized epilepsy - PMID:29445472 — Chinen Y et al. Clin Case Rep 2018 - PMID:29429203 — Zhang R et al. Zhonghua Er Ke Za Zhi 2018 - PMID:32132929 — Lichtig H et al. Front Physiol 2020 — Xenopus model - PMID:32517662 — Yang L et al. BMC Pediatr 2020 — imaging - PMID:33242595 — Yu KP et al. Eur J Med Genet 2021 — MCR genotype-phenotype - PMID:33751773 — Cuddapah VA et al. Am J Med Genet A 2021 — ASXL family spectrum - PMID:34086428 — Ikekwere JC et al. Prim Care Companion CNS Disord 2021 — psychiatric comorbidity - PMID:34436830 — Schirwani S et al. Am J Med Genet A 2021 — 45 unpublished individuals - PMID:35172777 — Khan TR et al. BMC Neurol 2022 — breath-holding + intractable epilepsy - PMID:35361921 — Awamleh Z et al. Eur J Hum Genet 2022 — DNAm signature (ASXL3 control-like) - PMID:35733401 — Slatnick LR et al. Pediatr Blood Cancer 2023 — B-ALL case - PMID:35863334 — Švantnerová J et al. Neuropediatrics 2022 — dystonic CP - PMID:36177608 — Schirwani S et al. Am J Med Genet A 2023 — familial inheritance, milder phenotype - PMID:36249891 — Scheithauer M et al. Behav Anal Pract 2023 — ABA for self-injury - PMID:37435360 — Liu Z et al. Biochem Biophys Rep 2023 — cardiomyocyte / biallelic missense - PMID:38027485 — Ayoub MC et al. Front Neurosci 2023 — motor phenotyping BOS vs BRS - PMID:38420660 — Woods E et al. Clin Genet 2024 — molecular phenotyping review - PMID:38711055 — Arai Y et al. BMC Pediatr 2024 — adolescent-onset feeding difficulty - PMID:38791157 — Kim N et al. Int J Mol Sci 2024 — ASXL family epigenetics review - PMID:39610869 — Ling S et al. Front Neurosci 2024 - PMID:39698206 — Geiser M et al. Front Psychiatry 2024 — pregabalin - PMID:39833101 — Trujillano L et al. Clin Genet 2025 — Spanish cohort n=22 - PMID:40237215 — Aşık A et al. Am J Med Genet A 2025 — dentofacial - PMID:40552904 — Woods E et al. Am J Med Genet A 2025 — International Natural History Study - PMID:40808361 — Piring A et al. Am J Med Genet A 2026 — pubertal timing - PMID:40980137 — Zhao B et al. Front Pediatr 2025 — paternal mosaicism - PMID:41458212 — Yang M et al. Front Genet 2025 — 15q11.2 modifier - PMID:41659201 — Yang Q et al. Front Neurosci 2025 — four Chinese patients - PMID:42111080 — Yaddanapudi S et al. Front Neurol 2026 — rehabilitation framework - PMID:42194125 — Mariano D et al. Children (Basel) 2026 — familial, maternal mosaicism - PMID:42494517 — Woods E et al. Genet Med Open 2026 — 204 individuals, NMD/MCR analysis - bioRxiv PPR1237608 — Ding C et al. 2026 — ASXL3–thyroid hormone–PV interneuron axis (preprint)

Databases and resources - GeneReviews: ASXL3-Related Disorder (NBK563693) — Balasubramanian M, Schirwani S - OMIM 615485 (403 during this session; identifiers confirmed via MONDO/Orphanet xrefs) · OMIM 615115 - MONDO:0014205 via OLS4 - Orphanet ORPHA:352577 — Orphadata API · epidemiology - HPO annotations for OMIM:615485 - ClinGen ASXL3 gene curation · ClinGen ASXL3 dosage sensitivity - UniProt Q9C0F0 - NCBI Gene 80816 · ClinVar ASXL3 - MGI:2685175 (mouse Asxl3) · IMPC Asxl3 - SFARI Gene: ASXL3 — score 1S (High Confidence, Syndromic) - Human Protein Atlas: ASXL3 - NORD: ASXL3-Related Disorder · ARRE Foundation